BioPharma Dive August 28, 2024
The deal with NextRNA Therapeutics, which could be worth up to $547 million, centers on the biotech’s technology to target long, non-coding RNA.
Bayer and biotechnology company NextRNA Therapeutics on Wednesday said they have partnered to develop a new kind of small molecule drug for cancer, agreeing to a collaboration deal that could be worth more than half of a billion dollars.
The two companies will use NextRNA’s technology to advance two small molecule drugs that target cancers driven by dysregulated long non-coding RNA. Under the deal, NextRNA could receive up to $547 million, including an upfront payment the companies did not disclose.
The companies also did not specify the types of cancer or specific drug targets they will pursue,...
Today's Sponsors
Today's Sponsor